Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 5/20 | 0.45 |
| ▸ | APOB | P04114 | 3/20 | 0.45 |
| ▸ | MTTP | P55157 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | TMPRSS2 | O15393 | 2/20 | 0.42 |
| ▸ | SMO | Q99835 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6644649 | 0.82 | NAMPT (0.42) | NAMPTNPC1RAB9ASMOHIF1A | |
| SCHEMBL6489620 | 0.80 | ABCB1 (0.51) | HIF1AEPAS1 | |
| SCHEMBL6501845 | 0.75 | NOD1 (0.47) | NPC1RAB9AHIF1AEPAS1HTT | |
| SCHEMBL6491162 | 0.75 | NOD1 (0.48) | RAB9AHIF1AEPAS1SMN1; SMN2 | |
| SCHEMBL16572137 | 0.75 | NPC1 (0.53) | APOBMTTPNPC1SMO | |
| SCHEMBL6488027 | 0.74 | ESR2 (0.50) | NAMPTAPOBMTTPNPC1RAB9A | |
| SCHEMBL6489208 | 0.74 | NOD1 (0.41) | RAB9AHIF1AEPAS1SMN1; SMN2 | |
| SCHEMBL6974436 | 0.74 | MTTP (0.53) | APOBMTTPNPC1RAB9ATMPRSS2 | |
| SCHEMBL6487719 | 0.73 | MELK (0.51) | APOBMTTP | |
| SCHEMBL6498841 | 0.73 | CLPP (0.52) | NPC1RAB9AHIF1AEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1472226-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003045921-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | NAMPT 2426/4885APOB 1/4885MTTP 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.